ST Pharm
CDMO and CRO company providing integrated drug development services across small molecules, oligonucleotides and RNA therapeutics. Offers end-to-end capabilities from discovery and preclinical non‑clinical assessment through cGMP manufacturing, QC/QA, clinical support and regulatory affairs, with on‑site R&D and global affiliate collaborations.
Industries
Nr. of Employees
medium (51-250)
ST Pharm
Seoul Office: 7F, I Park Tower Bldg., Yeongdongdae-ro 520, Gangnam-gu, Seoul 06170
Patents
Method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
US-10501403-B2
View Details
Method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
US-10501403-B2
View DetailsProducts
RNA therapeutic development platforms
Platform-based development capabilities for RNA therapeutics including mRNA and circular RNA and associated delivery/engineering for cell therapy applications (e.g., CAR‑NKT approaches).
RNA therapeutic development platforms
Platform-based development capabilities for RNA therapeutics including mRNA and circular RNA and associated delivery/engineering for cell therapy applications (e.g., CAR‑NKT approaches).
Services
Contract development and manufacturing services for small molecules, oligonucleotides and mRNA therapeutics across development and commercial supply stages.
In vivo non‑clinical safety and toxicology studies for preclinical development.
Remote and collaborative R&D services, including computational support and management of affiliate research partnerships.
Regulatory strategy and submission support to pursue global approvals.
Contract development and manufacturing services for small molecules, oligonucleotides and mRNA therapeutics across development and commercial supply stages.
In vivo non‑clinical safety and toxicology studies for preclinical development.
Remote and collaborative R&D services, including computational support and management of affiliate research partnerships.
Regulatory strategy and submission support to pursue global approvals.
Expertise Areas
- CDMO for small molecules
- Oligonucleotide therapeutics development
- mRNA and RNA therapeutics manufacturing
- cGMP manufacturing and QC/QA
Key Technologies
- mRNA therapeutics
- Circular RNA (circRNA)
- Oligonucleotide synthesis
- Small-molecule API production
News & Updates
Announcement of the company's first sustainability report.
Participation in TIDES USA 2025 to expand RNA therapeutics engagement in North America.
Notice of completed patient enrollment for an interim analysis of a Phase 2a clinical study.
Reported over 30 years of track record, 40+ global CDMO projects, and stated oligonucleotide and mRNA capacities.
Announcement of the company's first sustainability report.
Participation in TIDES USA 2025 to expand RNA therapeutics engagement in North America.
Notice of completed patient enrollment for an interim analysis of a Phase 2a clinical study.
Reported over 30 years of track record, 40+ global CDMO projects, and stated oligonucleotide and mRNA capacities.